Targeting leukaemia stem cells through inhibition of telomerase

通过抑制端粒酶靶向白血病干细胞

• 批准号: nhmrc : 1098516
• 负责人: A/Pr Steven Lane
• 金额: $ 44.68万
• 依托单位: Queensland Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-leukaemia-stem-inhibition-telomerase/662387
• 关键词: Targeting; leukaemia; stem; cells; through

Acute myeloid leukaemia (AML) is a type of very aggressive blood cancer that kills up to 1000 Australians every year. We use chemotherapy to treat AML, however, most patients are not cured by chemotherapy alone and the disease eventually comes back (relapses). We are looking at a new type of treatment for patients with AML that targets the genetic material (DNA) within the leukaemia cells. Our work has shown that this new type of treatment may prevent relapse after chemotherapy.

急性骨髓性白血病（AML）是一种非常具有侵袭性的血癌，每年导致多达1000名澳大利亚人死亡。我们使用化疗来治疗AML，然而，大多数患者不能单独通过化疗治愈，疾病最终会复发（复发）。我们正在寻找一种针对白血病细胞内遗传物质（DNA）的AML患者的新型治疗方法。我们的工作表明，这种新型治疗方法可以防止化疗后复发。